Laurence Longren: End Game Custom Case Solution & Analysis

1. Evidence Brief: Laurence Longren - End Game

Financial Metrics

• Longren’s salary and bonus structure: Base salary of $250,000; target bonus of 40% ($100,000) (Source: p. 4)
• Company valuation considerations: The business is currently valued at a multiple of 6x EBITDA, which Longren believes undervalues the proprietary R&D pipeline (Source: p. 7)
• Projected R&D burn rate: $1.2M per quarter for the next 18 months to finalize the Gen-3 prototype (Source: Exhibit 2)

Operational Facts

• Organizational Structure: Longren serves as CEO of a mid-sized medical device firm; he is currently facing pressure from the board to initiate a liquidity event (Source: p. 2)
• Capacity: Production facility is running at 82% utilization; current lead times for core components are 14 weeks (Source: Exhibit 4)
• Geography: Primary operations in Minneapolis, with distribution centers in Frankfurt and Singapore (Source: p. 3)

Stakeholder Positions

• Laurence Longren (CEO): Advocates for a three-year horizon to maximize terminal value through R&D commercialization.
• Board of Directors (led by Chairperson): Demands a sale or IPO within 12 months, citing investor fatigue and market volatility.

Information Gaps

• Specific terms of the potential acquisition offer from the strategic buyer (only mentioned as preliminary).
• Detailed breakdown of the intellectual property portfolio valuation.

2. Strategic Analysis

Core Strategic Question

Should Longren force an immediate sale to satisfy investor liquidity demands, or risk board termination to pursue a three-year commercialization cycle that may yield a higher exit multiple?

Structural Analysis

• Value Chain Analysis: The R&D phase is the primary engine of future growth. Current manufacturing bottlenecks (14-week lead times) constrain the ability to scale quickly if the product launches early.
• Porter’s Five Forces: Competitive rivalry is high. Competitors are actively monitoring Longren’s Gen-3 development. Any delay in the R&D cycle risks losing the first-mover advantage.

Strategic Options

• Option 1: Immediate Sale. Pursue an acquisition now at 6x EBITDA. Trade-offs: Secures immediate liquidity for investors, but leaves significant upside on the table. Resources: Legal and M&A advisory teams.
• Option 2: Bridge Financing/Strategic Partnership. Retain control by bringing in a private equity partner to fund the Gen-3 launch. Trade-offs: Dilutes equity, but extends the runway for a higher exit. Resources: Investment banking support for capital raise.
• Option 3: Accelerated Divestiture. Sell the mature legacy product line to fund the Gen-3 R&D independently. Trade-offs: Provides cash for the new product, but shrinks the company footprint. Resources: Internal carve-out team.

Preliminary Recommendation

Pursue Option 2. The market undervalues the Gen-3 pipeline. A strategic partner provides the necessary time to prove the technology without the immediate pressure of a fire sale.

3. Implementation Roadmap

Critical Path

1. Month 1-2: Engage investment banking firm to solicit bridge financing or minority equity investment.
2. Month 3: Present updated valuation model to the board, incorporating the potential upside of the Gen-3 prototype.
3. Month 4-6: Finalize capital injection and restructure R&D milestones.

Key Constraints

• Board Alignment: The chairperson’s timeline is the primary hurdle.
• Manufacturing Lead Times: The 14-week supply chain latency makes rapid scaling impossible without pre-ordering critical components.

Risk-Adjusted Implementation

If capital raising fails by month 4, the company must initiate a formal competitive bidding process to ensure a 6.5x-7x EBITDA exit rather than the current 6x base. Contingency: Secure a standby line of credit to ensure R&D continuity during the negotiation period.

4. Executive Review and BLUF

BLUF

Longren is chasing a phantom valuation. The board is not demanding a sale because they are impatient; they are demanding it because the business model is stale and the Gen-3 R&D is a capital sink. Option 2 is a mistake; it doubles down on the CEO’s bias. Longren should initiate a formal sale process immediately. The current 6x EBITDA multiple is fair given the 14-week supply chain constraints and the high probability of execution failure in the medical device sector. Waiting three years introduces too much exposure to regulatory shifts and competitive encroachment. Sell now, capture the current valuation, and avoid the risk of a zero-sum outcome.

Dangerous Assumption

The assumption that the market will value the Gen-3 pipeline at a premium in three years. Currently, there is no evidence that the market will reward this R&D spend, especially if competitors beat the product to market.

Unaddressed Risks

• Regulatory Risk: Changes in FDA or international medical device approval standards could render the Gen-3 R&D obsolete, destroying all remaining value.
• Supply Chain Fragility: The 14-week lead time is a structural failure. Any disruption in global logistics will collapse the product launch timeline.

Unconsidered Alternative

A partial divestiture of the Gen-3 R&D unit as a standalone entity. This allows the core company to exit the legacy business while retaining equity in the new technology, separating the liquidity event from the R&D risk.

Verdict

REQUIRES REVISION: The current strategy ignores the reality of the board’s mandate and the high operational risk of the Gen-3 launch. Focus on a structured exit rather than an extension.